Stock Track | NovoCure Shares Surge After Q3 Earnings Beat Estimates

Stock Track10-30 19:05

Shares of NovoCure (NASDAQ:NVCR) soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.

The oncology company reported a quarterly loss of $0.28 per share, narrower than the $0.33 per share loss that analysts had anticipated. Revenue for the quarter came in at $155.09 million, beating the consensus estimate of $143.95 million and representing a 21.8% increase from the same period last year.

The strong quarterly results were driven by continued adoption of NovoCure's Tumor Treating Fields therapy for various cancer types. The company highlighted increasing demand for its products used to treat malignant pleural mesothelioma and non-small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144423714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144423714","market":"us","top_or_hot":-1,"title":"Stock Track | NovoCure Shares Surge After Q3 Earnings Beat Estimates","media":"Stock Track","content":"<p>Shares of NovoCure (NASDAQ:NVCR) soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.</p>\n\n<p>The oncology company reported a quarterly loss of $0.28 per share, narrower than the $0.33 per share loss that analysts had anticipated. Revenue for the quarter came in at $155.09 million, beating the consensus estimate of $143.95 million and representing a 21.8% increase from the same period last year.</p>\n\n<p>The strong quarterly results were driven by continued adoption of NovoCure's Tumor Treating Fields therapy for various cancer types. The company highlighted increasing demand for its products used to treat malignant pleural mesothelioma and non-small cell lung cancer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Shares Surge After Q3 Earnings Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Shares Surge After Q3 Earnings Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-30 19:05 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of NovoCure (NASDAQ:NVCR) soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.\nThe oncology company ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1144423714","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144423714","pubTimestamp":1730286301,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of NovoCure  soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.The oncology company reported a quarterly loss of $0.28 per share, narrower than the $0.33 per share loss that analysts had anticipated. Revenue for the quarter came in at $155.09 million, beating the consensus estimate of $143.95 million and representing a 21.8% increase from the same period last year.The strong quarterly results were ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"股票追踪NovoCure股价在第三季度盈利超出预期后飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"Shares of NovoCure (NASDAQ:NVCR) soared nearly 6% in pre-market trading on Tuesday, following the company's third quarter earnings report that topped Wall Street expectations.\nThe oncology company reported a quarterly loss of $0.28 per share, narrower than the $0.33 per share loss that analysts had anticipated. Revenue for the quarter came in at $155.09 million, beating the consensus estimate of $143.95 million and representing a 21.8% increase from the same period last year.\nThe strong quarterly results were driven by continued adoption of NovoCure's Tumor Treating Fields therapy for various cancer types. The company highlighted increasing demand for its products used to treat malignant pleural mesothelioma and non-small cell lung cancer.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144423714"}